

ISSUE @ A GLANCE



Treatment of heart failure with reduced ejection fraction the dawn of the era of sodium-glucose co-transporter-2 inhibitors

F. Crea

3379

CardioPulse

2020 Vision: Introducing the New ESC Board

J. Ozkan

3384

COVID-19 and Katrina: recalcitrant racial disparities

H.G.C. Van Spall, C. W. Yancy, and K. C. Ferdinand

3390

The stethoscope: a potential vector for COVID-19?

R.S. Vasudevan, K. Bin Thani, D. Aljawder, S. Maisel, and A.S. Maisel

3393

Dr Norman M. Kaplan (1931-2020): a giant in the field of hypertension has departed

C. Venkata S. Ram

3395

References in CardioPulse articles

A. Tofield

3397

VIEWPOINT

Heart failure

Totality of evidence in trials of sodium-glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice

J. Butler, F. Zannad, G. Filippatos, S.D. Anker, and M. Packer

3398


CLINICAL RESEARCH

Heart failure

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

M. Serenelli, M. Böhm, S.E. Inzucchi, L. Køber, M.N. Kosiborod, F.A. Martinez, P. Ponikowski, M.S. Sabatine, S.D. Solomon, D.L. DeMets, O. Bengtsson, M. Sjöstrand, A.M. Langkilde, I.S. Anand, C.-E. Chiang, V.K. Chopra, R.A. de Boer, M. Diez, A. Dukát, J. Ge, J.G. Howlett, T. Katova, M. Kitakaze, C.E.A. Ljungman, S. Verma, K.F. Docherty, P.S. Jhund, and J.J.V. McMurray; on behalf of the DAPA-HF Investigators and Committees

3402



Editorial

The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns

G. Savarese and F. Cosentino

3419

A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial

A.J.M. Brown, S. Gandy, R. McCrimmon, J.G. Houston, A.D. Struthers, and C.C. Lang

3421

Editorial

Regression of left ventricular hypertrophy with SGLT2 inhibitors


F. Paneni, S. Costantino, and N. Hamdani

3433

8 Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study

M. Zabel, R. Willems, A. Lubinski, A. Bauer, J. Brugada, D. Conen, P. Flevari, G. Hasenfuß, M. Svetlosak, H.V. Huikuri, M. Malik, N. Pavlović, G. Schmidt, R. Sriharan, S. Schlögl, J. Szavits-Nossan, V. Traykov, A.E. Tuinenburg, S.N. Willich, M. Harden, T. Friede, J.H. Svendsen, C. Sticherling, and B. Merkely; the EU-CERT-ICD Study Investigators

3437



Editorial

Primary prevention of sudden death with the implantable cardioverter defibrillator: bridging the evidence gap

N.A. Mark Estes and S. Saba

3448

Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial

R.R. Makkar, D.J. Kereiakes, F. Aguirre, G. Kowalchuk, T. Chakravarty, K. Malliaras, G.S. Francis, T.J. Povsic, R. Schatz, J.H. Traverse, J.M. Pogoda, R.R. Smith, L. Marbán, D.D. Ascheim, M.R. Ostovaneh, J.A.C. Lima, A. DeMaria, E. Marbán, and T.D. Henry

3451

Editorial

Cardiovascular regenerative and reparative medicine: is myocardial infarction the model?

R. Sanz-Ruiz and F. Fernández-Avilés

3459

TRANSLATIONAL RESEARCH

Heart failure

8 Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy

J. Viereck, A. Bührke, A. Foinquinos, S. Chatterjee, J.A. Kleeberger, K. Xiao, H. Janssen-Peters, S. Batkai, D. Ramanujam, T. Kraft, S. Cebotari, F. Gueller, A.M. Beyer, J. Schmitz, J.H. Bräsen, J.D. Schmitto, M. Gyöngyösi, A. Löser, M.N. Hirt, T. Eschenhagen, S. Engelhardt, C. Bär, and T. Thum

3462

Editorial

Long non-coding RNA H19: a new avenue for RNA therapeutics in cardiac hypertrophy?

C. Pagiatakis, I.F. Hall, and G. Condorelli

3475

STATE OF THE ART REVIEW

Heart failure

Omics phenotyping in heart failure: the next frontier

A. Bayes-Genis, P.P. Liu, D.E. Lanfear, R.A. de Boer, A. González, T. Thum, M. Emdin, and J.L. Januzzi

3477

DISCUSSION FORUM

Heart failure development in obesity: mechanistic pathways

K. Karason and S. Jamaly

3485

CARDIOVASCULAR FLASHLIGHT

The heavy heart of HFpEF

B.A. Borlaug and J.J. Maleszewski

3447

Apical sparing on speckle tracking in Morbus Fabry

P. Suwalski, K. Klingel, U. Landmesser, and B. Heidecker

3486

Supremacy of echocardiography in the diagnostic workup of systemic AL amyloidosis

F. Carbone, M. Labate, F. Montecucco, and M. Canepa

3487

Atrial wall thickening, fevers, and atrial fibrillation caused by immunoglobulin G4-related biatrial cardiomyopathy

T. Fukuma, N. Fujimoto, M. Ishiyama, and K. Dohi

3488

 Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org